Phase II Study Evaluating the Efficacy and Tolerance of Bevacizumab (Avastin) in HER2- Inflammatory Breast Cancer

Next Previous
Trial Profile

Phase II Study Evaluating the Efficacy and Tolerance of Bevacizumab (Avastin) in HER2- Inflammatory Breast Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Aromatase inhibitors; Cyclophosphamide; Docetaxel; Epirubicin; Fluorouracil; Tamoxifen
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms BEVERLY; BEVERLY1
  • Sponsors UNICANCER

    • Most Recent Events

    • 04 Aug 2017 Planned End Date changed from 1 Sep 2017 to 1 Mar 2018.
    • 28 Mar 2016 Results (n=100) published in the Lancet Oncology
    • 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top